



In Vitro Models of Cardiovascular Diseases and Toxicity

Guest Editor:

Dr. Federico Vozzi

Institute of Clinical Physiology,
National Research Council (CNR),
56124 Pisa, Italy

Deadline for manuscript
submissions:

closed (31 March 2025)

Message from the Guest Editor

Cardiovascular diseases are the leading cause of morbidity and mortality and a substantial economic burden on the healthcare system globally. Several factors participate in their development: some more established and studied (smoking, diabetes, hypercholesterolemia, genetics), others external, come to the fore more recently (pollution, chemical compounds, etc.). Cardiovascular diseases and evaluation of toxicity share a series of mechanisms at the cell level, presenting a quite level of complexity to study in humans or animals.

The use of in vitro systems could help obtain specific information on cellular responses, favoring the study of the pathophysiology of diseases as well as evaluating the effects on the cell biology of several chemical compounds. In particular, in vitro models, which take methodologies at the interface of different specialties (e.g., biology, genetics, bioengineering, bioinformatics, physics), could provide a more reliable and close-to-reality response to researchers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)